Galectin Therapeutics, Inc Earning Date (GALT)

USA |NASDAQ |USD

GALT Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
May 16, 2022 Mar 2022 - - $-0.11
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
May 16, 2022 Mar 2022 - - $0.00

Galectin Therapeutics, Inc's next earnings date is Monday, May 16, 2022 for the fiscal quarter ending Mar 2022.

GALT Earnings Date & History Chart

GALT Earnings & Revenue Forecast

GALT Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 1 $-0.70 $-0.70 $-0.70

GALT Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-0.70 $-0.70 $-0.66

GALT Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 1 $0.00 $0.00 $0.00

GALT Earnings Date & Revenue History

GALT Earnings History

|
Show More
Show More

GALT Revenue History

|
Show More
Show More

Galectin Therapeutics, Inc Next Earnings Date & Report

GALT Next Earnings Date & Report Preview: Mar 2022 (FQ)

GALT's next earnings date is Monday, May 16, 2022 for the fiscal quarter ending Mar 31, 2022.

Galectin Therapeutics, Inc Previous Earnings Dates & Reports

GALT Previous Earnings Date & Report Recap: Dec 2021 (FQ)

Galectin Therapeutics, Inc's previous earnings date was Mar 29, 2022 for its fiscal quarter ended Dec 31, 2021.

GALT Previous Earnings Date & Report Recap: Dec 2020 (FY)

Galectin Therapeutics, Inc's previous annual earnings date was Mar 31, 2021 for its fiscal year ended Dec 31, 2020.

GALT's earnings per share (EPS) was $-0.40, beating the consensus analysts forecast of $-0.43 by -6.98% , and higher than the previous year's EPS (Dec 2019) by -6.98%.

Revenues were $0.00.

The company reported a net income of $-23.46M.

Galectin Therapeutics, Inc reported a free cash flow of $-20.60M for its fiscal year, compared to $-10.85M a year ago.